The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...

LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, has entered into a business relationship with Kaneka, a global leader ...

In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...

Following the U.S. FDA’s March 11 approval of Novo Nordisk A/S’ glucagon-like peptide 1 receptor agonist, Wegovy (semaglutide), to reduce the risk of major ...